benzodiazepines | The Medical Letter Inc.

Matching articles for "benzodiazepines"

Edluar - A New Sublingual Formulation of Zolpidem

The Medical Letter on Drugs and Therapeutics • April 19, 2010; (Issue 1336)

Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem (Ambien, and others), has been approved by the FDA for treatment of...

Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem (Ambien, and others), has been approved by the FDA for treatment of insomnia.

Med Lett Drugs Ther. 2010 Apr 19;52(1336):29-30 | Show Full Introduction Hide Full Introduction

Drugs for Insomnia

The Medical Letter on Drugs and Therapeutics • March 1, 2009; (Issue 79)

The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or...

The majority of patients with insomnia do not have a predisposing psychiatric disease. Rather, untreated insomnia may be a risk factor for development of psychiatric problems such as depression or anxiety.

Treat Guidel Med Lett. 2009 Mar;7(79):23-6 | Show Full Introduction Hide Full Introduction

Tetrabenazine (Xenazine) for Huntington's Chorea

The Medical Letter on Drugs and Therapeutics • January 26, 2009; (Issue 1304)

Tetrabenazine (Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with...

Tetrabenazine (Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with Huntington's disease. It has been available in other countries for decades.

Med Lett Drugs Ther. 2009 Jan 26;51(1304):7-8 | Show Full Introduction Hide Full Introduction

Drugs That May Cause Psychiatric Symptoms

The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Click here to view the free full article.

Med Lett Drugs Ther. 2008 Dec 15;50(1301):100-3 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)

The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...

Treat Guidel Med Lett. 2008 Jan;6(65):1-8 | Show Full Introduction Hide Full Introduction

Pharmaceutical Drug Overdose

The Medical Letter on Drugs and Therapeutics • September 1, 2006; (Issue 49)

Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in...

Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.

Treat Guidel Med Lett. 2006 Sep;4(49):61-6 | Show Full Introduction Hide Full Introduction

Drugs for Psychiatric Disorders

The Medical Letter on Drugs and Therapeutics • June 1, 2006; (Issue 46)

Drugs are not the only treatment for psychiatric illness. Psychotherapy remains an important component in the management of these disorders, and cognitive behavioral therapy (CBT) is used for many of them as well. Electroconvulsive therapy (ECT) has a long history of efficacy and safety when drugs are ineffective or cannot be used.

Treat Guidel Med Lett. 2006 Jun;4(46):35-46 | Show Full Introduction Hide Full Introduction

Drugs for Insomnia

The Medical Letter on Drugs and Therapeutics • February 1, 2006; (Issue 42)

Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective and durable than treatment with drugs. Hypnotic drugs are generally FDA-approved only for short-term use, but in practice they often are taken much longer.

Treat Guidel Med Lett. 2006 Feb;4(42):5-10 | Show Full Introduction Hide Full Introduction

Drugs in the Elderly

The Medical Letter on Drugs and Therapeutics • January 16, 2006; (Issue 1226)

The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse...

The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse effects.

Med Lett Drugs Ther. 2006 Jan 16;48(1226):6-7 | Show Full Introduction Hide Full Introduction

Ambien CR for Insomnia

The Medical Letter on Drugs and Therapeutics • December 5, 2005; (Issue 1223)

Zolpidem (Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has received...

Zolpidem (Ambien - Sanofi-Aventis), a nonbenzodiazepine benzodiazepine receptor agonist, is the most frequently prescribed hypnotic in the US. As its patent approaches expiration, its manufacturer has received FDA approval to market an extended-release formulation of the drug, Ambien CR. The pharmacological rationale for doing so is that short-acting hypnotics like zolpidem are more effective at inducing sleep than they are at maintaining it.

Med Lett Drugs Ther. 2005 Dec 5;47(1223):97-8 | Show Full Introduction Hide Full Introduction

Ramelteon (Rozerem) for Insomnia

The Medical Letter on Drugs and Therapeutics • November 7, 2005; (Issue 1221)

Ramelteon (Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are...

Ramelteon (Rozerem - Takeda), a melatonin receptor agonist, has been approved by the FDA for treatment of insomnia characterized by difficulty falling asleep. Unlike all other prescription hypnotics, which are classified as schedule IV drugs, ramelteon is not a controlled substance.

Med Lett Drugs Ther. 2005 Nov 7;47(1221):89-91 | Show Full Introduction Hide Full Introduction

Ropinirole for Restless Legs Syndrome

The Medical Letter on Drugs and Therapeutics • August 1, 2005; (Issue 1214)

Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs...

Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).

Med Lett Drugs Ther. 2005 Aug 1;47(1214):62-4 | Show Full Introduction Hide Full Introduction

CYP3A and Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 4, 2005; (Issue 1212)

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.

Med Lett Drugs Ther. 2005 Jul 4;47(1212):54-5 | Show Full Introduction Hide Full Introduction

Eszopiclone (Lunesta), a New Hypnotic

The Medical Letter on Drugs and Therapeutics • February 28, 2005; (Issue 1203)

Eszopiclone (Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone (Imovane, and others in Canada), which has been...

Eszopiclone (Lunesta - Sepracor), a benzodiazepine-like drug, has been approved by the FDA for oral treatment of insomnia. It is the S-isomer of zopiclone (Imovane, and others in Canada), which has been available in other countries for almost 20 years. Unlike similar drugs such as zolpidem (Ambien) or zaleplon (Sonata), Lunesta is not being restricted in its labeling to short-term use. Like other hypnotics, eszopiclone is a schedule IV drug.

Med Lett Drugs Ther. 2005 Feb 28;47(1203):17-9 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • February 1, 2005; (Issue 30)

The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the...

The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.

Treat Guidel Med Lett. 2005 Feb;3(30):7-14 | Show Full Introduction Hide Full Introduction

Alprazolam (Xanax, and others) Revisited

The Medical Letter on Drugs and Therapeutics • January 17, 2005; (Issue 1200)

Alprazolam, a short-acting benzodiazepine, is one of the most widely prescribed drugs in the US. It is approved by the FDA for treatment of anxiety and panic disorder. An extended-release formulation, Xanax XR,...

Med Lett Drugs Ther. 2005 Jan 17;47(1200):5-7 | Show Full Introduction Hide Full Introduction

Drug Interactions with Grapefruit Juice

The Medical Letter on Drugs and Therapeutics • January 5, 2004; (Issue 1173)

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice...

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).

Med Lett Drugs Ther. 2004 Jan 5;46(1173):2-4 | Show Full Introduction Hide Full Introduction

Drugs for Psychiatric Disorders

The Medical Letter on Drugs and Therapeutics • July 1, 2003; (Issue 11)

The number of drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions, 2003.

Treat Guidel Med Lett. 2003 Jul;1(11):69-76 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.

Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 | Show Full Introduction Hide Full Introduction

Xanax XR for Panic Disorder

The Medical Letter on Drugs and Therapeutics • May 26, 2003; (Issue 1157)

The FDA has approved an extended-release (XR) formulation of the benzodiazepine alprazolam (Xanax XR - Pfizer) for treatment of panic disorder, with or without agoraphobia. The new formulation is intended to...

The FDA has approved an extended-release (XR) formulation of the benzodiazepine alprazolam (Xanax XR - Pfizer) for treatment of panic disorder, with or without agoraphobia. The new formulation is intended to reduce the need for frequent dosing and problems of interdose anxiety. This review describes the effectiveness of the extended-release formulation, as well as sections on dependence, abuse and withdrawal, adverse effects, and drug interactions. The review concludes with an overall assessment of the drug's efficacy and cost.

Med Lett Drugs Ther. 2003 May 26;45(1157):43-4 | Show Full Introduction Hide Full Introduction

Tests for Drugs of Abuse

The Medical Letter on Drugs and Therapeutics • August 19, 2002; (Issue 1137)

Testing for drug use has become increasingly common, not only in health care, but also in drug rehabilitation, in the military, at the workplace, after accidents and in the criminal justice system. Performance-enhancing drugs such as anabolic steroids, growth hormone (Genotropin, and others) and erythropoietin (Procrit, Epogen) are not discussed here.

Med Lett Drugs Ther. 2002 Aug 19;44(1137):71-3 | Show Full Introduction Hide Full Introduction

Drugs That May Cause Psychiatric Symptoms

The Medical Letter on Drugs and Therapeutics • July 8, 2002; (Issue 1134)

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Med Lett Drugs Ther. 2002 Jul 8;44(1134):59-62 | Show Full Introduction Hide Full Introduction

Acute Reactions to Drugs of Abuse

The Medical Letter on Drugs and Therapeutics • March 4, 2002; (Issue 1125)

Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and...

Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.

Med Lett Drugs Ther. 2002 Mar 4;44(1125):21-4 | Show Full Introduction Hide Full Introduction

Drugs that may cause Cognitive Disorders in the Elderly

The Medical Letter on Drugs and Therapeutics • November 27, 2000; (Issue 1093)

Older patients are especially susceptible to drug-induced cognitive impairment. They are more likely to be taking multiple drugs, to have higher blood levels of those drugs because of renal or hepatic dysfunction, and to have pre-existing cognitive problems that make it difficult to detect the role of drugs causing new symptoms or making old ones worse.

Med Lett Drugs Ther. 2000 Nov 27;42(1093):111-2 | Show Full Introduction Hide Full Introduction

Hypnotic Drugs

The Medical Letter on Drugs and Therapeutics • August 7, 2000; (Issue 1084)

Superseded by Drugs of Choice HandbookMany drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be...

Superseded by Drugs of Choice Handbook
Many drugs are used to treat insomnia, but for some patients nonpharmacological treatments such as changing sleep habits, relaxation training and cognitive therapy may be more effective than drugs.

Med Lett Drugs Ther. 2000 Aug 7;42(1084):71-2 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 2, 1999; (Issue 1056)

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new...

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2;41(1056):59-62 | Show Full Introduction Hide Full Introduction

Drugs for Depression and Anxiety

The Medical Letter on Drugs and Therapeutics • April 9, 1999; (Issue 1050)

The number of drugs marketed for treatment of depression has increased in recent years. Antidepressants are generally also effective for treatment of...

The number of drugs marketed for treatment of depression has increased in recent years. Antidepressants are generally also effective for treatment of anxiety.

Med Lett Drugs Ther. 1999 Apr 9;41(1050):33-8 | Show Full Introduction Hide Full Introduction

Drugs for Psychiatric Disorders

The Medical Letter on Drugs and Therapeutics • April 11, 1997; (Issue 998)

The number of new drugs marketed for psychiatric indications has increased sharply in recent years. The recommendations in this article are based on the results of controlled trials and on the experience and opinions of Medical Letter consultants. Interactions with other drugs can be found in The Medical Letter Handbook of Adverse Drug Interactions, 1997.

Med Lett Drugs Ther. 1997 Apr 11;39(998):33-40 | Show Full Introduction Hide Full Introduction

Hypnotic Drugs

The Medical Letter on Drugs and Therapeutics • July 5, 1996; (Issue 978)

Superseded by Drugs of Choice HandbookInsomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including...

Superseded by Drugs of Choice Handbook
Insomnia is a commom complaint, particularly among the elderly. Many drugs are approved by the US Food and Drug Administration (FDA) for treatment of insomnia, including five benzodiazepines and zolpidem (Ambien), a non-benzodiazepine that binds to benzodiazepine receptors in the brain. Some drugs marketed for other indications, such as antihistamines, antidepressants and antipsychotics, are also used as hypnotics. For many patients, nonpharmacological treatment of insomnia may be more effective than drugs, especially in the long term (CM Morin et al, Am J Psychiatry, 151:1172, 1994).

Med Lett Drugs Ther. 1996 Jul 5;38(978):59-61 | Show Full Introduction Hide Full Introduction

Acute Reactions to Drugs of Abuse

The Medical Letter on Drugs and Therapeutics • May 10, 1996; (Issue 974)

Acute toxic reactions to drugs of abuse continue to be important problems. Since the last Medical Letter article on this subject (volume 32, page 92, 1990), new reactions and new approaches to treating them...

Med Lett Drugs Ther. 1996 May 10;38(974):43-6 | Show Full Introduction Hide Full Introduction

Drugs for Vomiting Caused by Cancer Chemotherapy

The Medical Letter on Drugs and Therapeutics • December 24, 1993; (Issue 912)

Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table...

Several currently available antiemetic drugs can prevent vomiting caused by cancer chemotherapy. Anticancer drugs that cause vomiting are listed in the table below.

Med Lett Drugs Ther. 1993 Dec 24;35(912):124-6 | Show Full Introduction Hide Full Introduction

Zolpidem For Insomnia

The Medical Letter on Drugs and Therapeutics • April 30, 1993; (Issue 895)

Zolpidem (Ambien - Searle), an imidazopyridine hypnotic available in Europe for several years, was recently approved by the US Food and Drug Administration for short-term treatment of...

Zolpidem (Ambien - Searle), an imidazopyridine hypnotic available in Europe for several years, was recently approved by the US Food and Drug Administration for short-term treatment of insomnia.

Med Lett Drugs Ther. 1993 Apr 30;35(895):35-6 | Show Full Introduction Hide Full Introduction

Clozapine

The Medical Letter on Drugs and Therapeutics • February 19, 1993; (Issue 890)

Clozapine (Clozaril - Sandoz), an antipsychotic drug, was first marketed in the USA three years ago (Medical Letter, 32:3, 1990). Because of its hematological toxicity, the US Food and Drug Administration...

Clozapine (Clozaril - Sandoz), an antipsychotic drug, was first marketed in the USA three years ago (Medical Letter, 32:3, 1990). Because of its hematological toxicity, the US Food and Drug Administration approved the drug only for patients with schizophrenia who cannot tolerate or do not respond to standard antipsychotic drugs.

Med Lett Drugs Ther. 1993 Feb 19;35(890):16-8 | Show Full Introduction Hide Full Introduction

Estazolam - A New Benzodiazepine Hypnotic

The Medical Letter on Drugs and Therapeutics • October 4, 1991; (Issue 854)

Estazolam (ProSom - Abbott), a triazolobenzodiazepine derivative similar in structure to alprazolam (Xanax) and triazolam (Halcion), was recently marketed in the USA for treatment of...

Estazolam (ProSom - Abbott), a triazolobenzodiazepine derivative similar in structure to alprazolam (Xanax) and triazolam (Halcion), was recently marketed in the USA for treatment of insomnia.

Med Lett Drugs Ther. 1991 Oct 4;33(854):91-2 | Show Full Introduction Hide Full Introduction

Alprazolam For Panic Disorder

The Medical Letter on Drugs and Therapeutics • April 5, 1991; (Issue 841)

Alprazolam (Xanax - Upjohn), a triazolobenzodiazepine previously available in the USA for treatment of anxiety (Medical Letter 24:41, 1982), was recently approved by the US Food and Drug Administration (FDA)...

Alprazolam (Xanax - Upjohn), a triazolobenzodiazepine previously available in the USA for treatment of anxiety (Medical Letter 24:41, 1982), was recently approved by the US Food and Drug Administration (FDA) for treatment of panic disorder, with or without agoraphobia. According to one report, alprazolam was the fifth most widely prescribed drug in the USA last year (American Medical News, March 4, 1991, page 4).

Med Lett Drugs Ther. 1991 Apr 5;33(841):30-1 | Show Full Introduction Hide Full Introduction

Acute Reactions to Drugs of Abuse

The Medical Letter on Drugs and Therapeutics • October 5, 1990; (Issue 828)

...

Med Lett Drugs Ther. 1990 Oct 5;32(828):92-4 | Show Full Introduction Hide Full Introduction

Balloon Dilatation Of The Prostate

The Medical Letter on Drugs and Therapeutics • June 29, 1990; (Issue 821)

To avoid the morbidity and occasional mortality of transurethral resection or open prostatectomy, some urologists are now using balloon dilatation of the prostatic urethra to treat benign prostatic...

Med Lett Drugs Ther. 1990 Jun 29;32(821):64 | Show Full Introduction Hide Full Introduction

Quazepam: A New Hypnotic

The Medical Letter on Drugs and Therapeutics • April 20, 1990; (Issue 816)

Quazepam (Doral - Baker Cummins, Wallace) is a trifluoroethyl benzodiazepine made by Schering and approved in 1985 by the US Food and Drug Administration for treatment of insomnia. Like other benzodiazepines,...

Quazepam (Doral - Baker Cummins, Wallace) is a trifluoroethyl benzodiazepine made by Schering and approved in 1985 by the US Food and Drug Administration for treatment of insomnia. Like other benzodiazepines, it is a Schedule IV controlled substance.Quazepam (Doral - Baker Cummins, Wallace) is a trifluoroethyl benzodiazepine made by Schering and approved in 1985 by the US Food and Drug Administration for treatment of insomnia. Like other benzodiazepines, it is a Schedule IV controlled substance.

Med Lett Drugs Ther. 1990 Apr 20;32(816):39-40 | Show Full Introduction Hide Full Introduction

Oral Hypnotic Drugs

The Medical Letter on Drugs and Therapeutics • March 10, 1989; (Issue 787)

Three benzodiazepines and 16 other compounds are marketed in the USA for treatment of insomnia. Many authorities believe that insomnia is overdiagnosed and overtreated (MK Erman, ed, Sleep Disorders,...

Med Lett Drugs Ther. 1989 Mar 10;31(787):23-4 | Show Full Introduction Hide Full Introduction

Choice of Benzodiazepines

The Medical Letter on Drugs and Therapeutics • February 26, 1988; (Issue 760)

Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the...

Since The Medical Letter last reviewed the choice of benzodiazepines (Volume 23, page 41, 1981), several new drugs have been marketed and some old ones are now available generically. Most of the benzodiazepines available for oral use in the USA are listed in the table on page 28.

Med Lett Drugs Ther. 1988 Feb 26;30(760):26-8 | Show Full Introduction Hide Full Introduction

Nabilone And Other Antiemetic For Cancer Patients

The Medical Letter on Drugs and Therapeutics • January 1, 1988; (Issue 756)

Nabilone (Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and...

Nabilone (Cesamet - Lilly), a synthetic cannabinoid chemically related to tetrahydrocannabinol (THC), the main active ingredient in marijuana, was recently marketed in the USA for oral treatment of nausea and vomiting associated with cancer chemotherapy. Oral THC itself, known generically as dronabinol (Marinol), is also commercially available as an antiemetic for cancer patients (Medical Letter, 27:97, 1985). Other drugs used for this purpose include metoclopramide (Reglan - Medical Letter, 24:67, 1982), prochlorperazine (Compazine; and others), haloperidol (Haldol; and others), and corticosteroids. Benzodiazepines, such as lorazepam (Ativan; and others), are used to treat anticipatory nausea and vomiting that occurs before chemotherapy begins.

Med Lett Drugs Ther. 1988 Jan 1;30(756):2-4 | Show Full Introduction Hide Full Introduction